文献

1. Landtblom AM, Flodin U, Karlsson M, et al. Multiple sclerosis and exposure to solvents, ionizing radiation and animals. Scand J Work Environ Health 1993;19:399–404.
2. Haahr S, Koch-Henriksen N, Moller-Larsen A, et al. Increased risk of multiple sclerosis after late Epstein-Barr virus infection: a historical prospective study. Mult Scler 1995;1:73–7.
3. Swank RL. Multiple sclerosis: fat-oil relationship. Nutrition 1991;7:368–76.
4. Esparza ML, Saski S, Kesteloot H. Nutrition, latitude, and multiple sclerosis mortality: an ecologic study. Am J Epidemiol 1995;142:733–7.
5. Ghadirian P, Jain M, Ducic S, et al. Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. Int J Epidemiol 1998;(5):845–52.
6. Malosse D, Perron H, Sasco A, Seigneurin JM. Correlation between milk and dairy product consumption and multiple sclerosis prevalence: a worldwide study. Neuroepidemiology 1992;11:304–12.
7. Tola MR, Granieri E, Malagu S, et al. Dietary habits and multiple sclerosis. A retrospective study in Ferrara, Italy. Acta Neurol (Napoli) 1994;16:189–97.
8. Esparza ML, Saski S, Kesteloot H. Nutrition, latitude, and multiple sclerosis mortality: an ecologic study. Am J Epidemiol 1995;142:733–7.
9. Ghadirian P, Jain M, Ducic S, et al. Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. Int J Epidemiol 1998;27:845–52.
10. Hadjivassiliou M, Gibson A, Davies-Jones GA, et al. Does cryptic gluten sensitivity play a part in neurological illness? Lancet 1996;347:369–71.
11. Mortensen JT, Bronnum-Hansen H, Rasmussen K. Multiple sclerosis and organic solvents. Epidemiology 1998;9:168–71.
12. Juntunen J, Kinnunen E, Antti-Poika M, Koskenvuo M. Multiple sclerosis and occupational exposure to chemicals: a co-twin control study of a nationwide series of twins. Br J Ind Med 1989;46:417–9.
13. Landtblom AM, Flodin U, Soderfeldt B, et al. Organic solvents and multiple sclerosis: a synthesis of the current evidence. Epidemiology 1996;7:429–33 [review].
14. Blisard KS, Kornfeld M, McFeeley PJ, Smialek JE. The investigation of alleged insecticide toxicity: a case involving chlordane exposure, multiple sclerosis, and peripheral neuropathy. J Forensic Sci 1986;31:1499–504.
15. Landtblom AM, Flodine U, Karlsson M, et al. Multiple sclerosis and exposure to solvents, ionizing radiation and animals. Scand J Work Environ Health 1993;19:399–404.
16. Krebs JM, Park RM, Boal WL. A neurological disease cluster at a manufacturing plant. Arch Environ Health 1995;50:190–5.
17. Emre M, de Decker C. Effects of cigarette smoking on motor functions in patients with multiple sclerosis. Arch Neurol 1992;49:1243–7.
18. Fung YK, Meade AG, Rack EP, Blotcky AJ. Brain mercury in neurodegenerative disorders. J Toxicol Clin Toxicol 1997;35:49–54.
19. Siblerud RL, Kienholz E. Evidence that mercury from silver dental fillings may be an etiological factor in multiple sclerosis. Sci Total Environ 1994;142:191–205.
20. Bangsi D, Ghadirian P, Ducic S, et al. Dental amalgam and multiple sclerosis: a case-control study in Montreal, Canada. Int J Epidemiol 1998;27:667–71.
21. Craelius W. Comparative epidemiology of multiple sclerosis and dental caries. J Epidemiol Community Health 1978;32:155–65.
22. Cendrowski W. Multiple sclerosis and MaxEPA. Br J Clin Pract 1986;40:365–7.
23. Bates D, Cartlidge NE, French JM, et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 1989;52:18–22.
24. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 2000;102:143–9.
25. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypothesis 1986;21:193–200.
26. DeLuca HF, Zierold C. Mechanisms and functions of vitamin D. Nutr Rev 1998;56(2 Pt 2):S4–10 [review].
27. Yasui M, Yase Y, Ando K, et al. Magnesium concentration in brains from multiple sclerosis patients. Acta Neurol Scand 1990;81:197–200.
28. Yasui M, Ota K. Experimental and clinical studies on dysregulation of magnesium metabolism and the aetiopathogenesis of multiple sclerosis. Magnes Res 1992;5:295–302.
29. Hayes CE, Cantorna MT, Deluca HF. Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med 1997;216:21–7.
30. Werbach M. Nutritional Influences on Illness. Tarzana, CA: Third Line Press, 1996, 434 [review].
31. Dworkin RH, Bates D, Millar JH, Paty DW. Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials. Neurology 1984;34:1441–5 [review].
32. Dines KC, Powell HC. Mast cell interactions with the nervous system: relationship to mechanisms of disease. J Neuropathol Exp Neurol 1997;56:627–40.
33. Stern EI. The intraspinal injection of vitamin B1 for the relief of intractable pain, and for inflammatory and degenerative diseases of the central nervous system. Am J Surg 1938;34:495.
34. Moore MT. Treatment of multiple sclerosis with nicotinic acid and vitamin B1. Arch Int Med 1940;65:18.
35. Koprowski H, Spitsin SV, Hooper DC. Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite. Ann Neurol 2001;49:139.
36. Koprowski H, Spitsin SV, Hooper DC. Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite. Ann Neurol 2001;49:139.
37. Korwin-Piotrowska T, Nocoñ D, Stankowska-Chomicz A, et al. Experience of Padma 28 in multiple sclerosis. Phytother Res 1992;6:133–6.
38. Brochet B, Orgogozo JM, Guinot P, et al. Pilot study of Ginkgolide B, a PAF-acether specific inhibitor in the treatment of acute outbreaks of multiple sclerosis. Rev Neurol (Paris) 1992;148:299–301 [in French].

• 
• 
• 
• 
• 
• 
• 
• 
• 
•